Xeris Pharmaceuticals, Inc. (XERS) Social Stream
XERIS BIOPHARMA HOLDINGS INC (XERS) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering XERS.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-10-29 | 4 | $11 | $4 | $7.75 | $2.93 | 164.51% |
| 2021-11-11 | 5 | $11 | $4.25 | $7.062 | $2.93 | 141.02% |
| 2021-12-14 | 5 | $11 | $4.25 | $6.85 | $2.93 | 133.79% |
| 2021-12-31 | 5 | $11 | $5.4 | $7.08 | $2.93 | 141.64% |
| 2022-01-10 | 5 | $11 | $5.4 | $7.48 | $2.93 | 155.29% |
| 2022-02-01 | 5 | $11 | $6 | $7.6 | $2.93 | 159.39% |
| 2022-03-23 | 4 | $7 | $6 | $6.25 | $2.93 | 113.31% |
| 2022-05-12 | 5 | $7 | $6 | $6.3 | $2.93 | 115.02% |
| 2022-10-19 | 4 | $6.5 | $6 | $6.125 | $2.93 | 109.04% |
| 2022-10-21 | 5 | $6.5 | $4 | $5.7 | $2.93 | 94.54% |
| 2022-11-10 | 5 | $6.5 | $4 | $5.5 | $2.93 | 87.71% |
| 2023-03-09 | 5 | $6 | $4 | $5 | $2.93 | 70.65% |
| 2023-08-10 | 4 | $6 | $4 | $5 | $2.93 | 70.65% |
| 2023-11-09 | 5 | $6 | $4 | $4.9 | $2.93 | 67.24% |
| 2023-11-13 | 5 | $5.5 | $4 | $4.6 | $2.93 | 57% |
The Trend in the Analyst Price Target
Over the past 22 months, XERS's average price target has gone down $3.
XERS reports an average of 203.78% for its upside potential over the past 41 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-09 | 5 | 6 | 4 | 5.0 | 1.25 | 300% |
| 2023-03-09 | 4 | 6 | 4 | 5.0 | 1.25 | 300% |
| 2023-05-10 | 4 | 6 | 4 | 5.0 | 2.93 | 70.65% |
| 2023-07-25 | 4 | 6 | 4 | 5.0 | 2.41 | 107.47% |
| 2023-08-28 | 5 | 6 | 4 | 4.9 | 2.27 | 115.86% |
XERS Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 5 | 0 | 0 | 0 | 0 | 5 |
The Trend in the Broker Recommendations
XERS's average broker recommendation rating improved by 0.75 over the prior 29 months.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- To contextualize these metrics, consider that out of all US stocks, XERIS BIOPHARMA HOLDINGS INC's average analyst price target is higher than 122.06% of them.
- To contextualize these metrics, consider that out of all US stocks, XERIS BIOPHARMA HOLDINGS INC's number of analysts covering the stock is higher than 383.88% of them.
- XERIS BIOPHARMA HOLDINGS INC's variance in analysts' estimates is lower than -801.88% of Healthcare stocks.
- XERS has a higher upside potential (average analyst target price relative to current price) than 1201.03% of stocks in the small market cap category.
Stocks similar to XERIS BIOPHARMA HOLDINGS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are VRCA, ITRM, and KNSA.
View All Top Stocks by Price Target
Make investment decisions regarding XERS using the data that counts. Try POWR Ratings for free.